Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Incyte Corp
(NQ:
INCY
)
65.09
-0.07 (-0.11%)
Streaming Delayed Price
Updated: 1:10 PM EDT, Aug 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Incyte Corp
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Incyte to Present Late-Breaking Phase 3 Results for Retifanlimab (Zynyz®) and Initial Data from Phase 1 CDK2 Inhibitor Program at the European Society of Medical Oncology (ESMO) Congress 2024
August 21, 2024
From
Incyte
Via
Business Wire
Incyte Seeks Expanded FDA Approval For Lymphoma Drug After Releasing Promising Topline Data From Late-Stage Study
August 16, 2024
Incyte's Phase 3 inMIND trial of Monjuvi (tafasitamab) combined with lenalidomide and rituximab meets primary endpoints in relapsed follicular lymphoma patients, showing positive progression-free...
Via
Benzinga
Exposures
Product Safety
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular Lymphoma
August 15, 2024
From
Incyte
Via
Business Wire
Analyst Expectations For Incyte's Future
August 15, 2024
Via
Benzinga
Analyst Ratings For Incyte
July 26, 2024
Via
Benzinga
Looking for growth without the hefty price tag? Consider NASDAQ:INCY.
July 22, 2024
INCYTE CORP (NASDAQ:INCY) is showing decent growth, but is still valued reasonably.
Via
Chartmill
NASDAQ:INCY is not too expensive for the growth it is showing.
July 01, 2024
In the world of growth stocks, INCYTE CORP (NASDAQ:INCY) shines as a value proposition.
Via
Chartmill
FDA Approves Incyte/Syndax Partnered Drug For Chronic Graft-Versus-Host Disease, A Post-Transplant Complication
August 15, 2024
The FDA has approved Incyte and Syndax Pharmaceuticals' Niktimvo for chronic graft-versus-host disease in patients after at least two prior therapies, providing new hope for those with this serious...
Via
Benzinga
Exposures
Product Safety
Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)
August 14, 2024
From
Incyte and Syndax Pharmaceuticals
Via
Business Wire
Incyte to Present at Upcoming Investor Conferences
August 13, 2024
From
Incyte
Via
Business Wire
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 07, 2024
From
Incyte
Via
Business Wire
Analyst Expectations For Incyte's Future
June 18, 2024
Via
Benzinga
Despite its growth, NASDAQ:INCY remains within the realm of affordability.
June 10, 2024
Don't overlook INCYTE CORP (NASDAQ:INCY)—a stock with solid growth prospects and a reasonable valuation.
Via
Chartmill
After Reporting Five Patient Deaths, Data Committee Recommends MacroGenics Halt Prostate Cancer Trial
July 31, 2024
MacroGenics will discontinue vobra duo for remaining mCRPC participants after five deaths. New data to be presented at ESMO 2024 conference.
Via
Benzinga
Topics
Death
Exposures
Death
Incyte's Q2 Earnings: Wider Than Expected Loss, Pipeline Review, Lifts Jakafi Sales Guidance
July 30, 2024
Incyte reported Q2 revenue of $1.04 billion, beating consensus, with Jakafi revenue at $705.9 million and Opzelura revenue up 52%. Despite an adjusted EPS loss, the company updated its 2024 Jakafi...
Via
Benzinga
Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
July 30, 2024
From
Incyte
Via
Business Wire
NASDAQ:INCY is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
July 10, 2024
INCYTE CORP (NASDAQ:INCY), an undervalued stock with good fundamentals.
Via
Chartmill
S&P 500 Hits Record Highs, Eyes 6th Straight Gain As Powell Keeps Bears At Bay; Tesla Targets 10th Consecutive Win, Bank Stocks Rally: What's Driving Markets Tuesday?
July 09, 2024
The S&P 500 index climbed to new all-time highs, rising 0.3% during Tuesday’s session, aiming for a potential sixth consecutive positive close and remaining resilient after Fed Chair Jerome Powell‘s...
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Incyte to Report Second Quarter Financial Results
July 09, 2024
From
Incyte
Via
Business Wire
The 3 Most Undervalued Cathie Wood Stocks to Buy in July 2024
July 09, 2024
The stock market watches this investing guru's picks closely but these may be the best undervalued Cathie Wood stocks in her ETFs.
Via
InvestorPlace
7 Cheap Biotech Stocks With Major Upside Potential
July 09, 2024
While the broader healthcare sector enjoys permanent relevance, you can potentially maximize your upside with cheap biotech stocks.
Via
InvestorPlace
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 08, 2024
From
Incyte
Via
Business Wire
3 Highly Rated Biotech Stocks for Your July Buy List
July 05, 2024
Discover three top-rated biotech stocks that are pushing forward the pharma and biotech revolution on Wall Street.
Via
InvestorPlace
This CrowdStrike Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
July 02, 2024
Via
Benzinga
Stocks Chop As Wall Street Unpacks Powell Comments
July 02, 2024
Stocks are mixed at midday, as investors weigh remarks from Federal Reserve Chair Jerome Powell.
Via
Talk Markets
Topics
Economy
Exposures
Interest Rates
7 Undervalued Biotech Stocks to Buy for Big-Time Returns
July 01, 2024
The broader healthcare sector enjoys a powerfully relevant narrative. Undervalued biotech stocks makes the case even more attractive.
Via
InvestorPlace
For those who appreciate value investing, NASDAQ:INCY is a compelling option with its solid fundamentals.
June 19, 2024
In a market where value is scarce, INCYTE CORP (NASDAQ:INCY) offers a refreshing opportunity with its solid fundamentals.
Via
Chartmill
Nasdaq 100, S&P 500 Close At Record Highs As Tech Stocks Reclaim Dominance: Thursday's Gainers & Losers
June 13, 2024
The Nasdaq 100 index posted its fourth consecutive session in the green on Thursday, closing at 19,576 points and reaching all-time highs.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Incyte Announces Final Results of Tender Offer
June 13, 2024
From
Incyte Corporation
Via
Business Wire
Incyte Announces Preliminary Results of Tender Offer
June 11, 2024
From
Incyte Corporation
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.